Hepa-mezh
Ask a doctor about a prescription for Hepa-mezh
How to use Hepa-mezh
Package Leaflet: Information for the User
Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.
Hepa-Merz
5 g/10 ml (0.5 g/ml), concentrate for solution for infusion
Ornithine aspartate
Read the leaflet carefully before using the medicine, as it contains important information for the patient.
- Keep this leaflet, so you can read it again if you need to.
- If you have any doubts, consult your doctor or pharmacist.
- This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
- If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.
Table of Contents of the Leaflet:
- 1. What is Hepa-Merz and what is it used for
- 2. Important information before using Hepa-Merz
- 3. How to use Hepa-Merz
- 4. Possible side effects
- 5. How to store Hepa-Merz
- 6. Contents of the pack and other information
1. What is Hepa-Merz and what is it used for
Hepa-Merz is a medicine that stimulates the removal of ammonia from the body by increasing the synthesis of urea in the liver. Hepa-Merz also supports the removal of ammonia from tissues other than the liver.
Hepa-Merz is used to treat hepatic encephalopathy in the course of acute and chronic liver diseases, such as fatty liver, cirrhosis, and hyperammonemia.
2. Important information before using Hepa-Merz
When not to use Hepa-Merz
Do not use Hepa-Merz in patients with the following disorders:
- hypersensitivity to L-ornithine L-aspartate;
- severe renal insufficiency (serum creatinine above 3 mg/100 ml);
- disorders of amino acid metabolism involved in the urea cycle, e.g., due to enzymatic defects.
Warnings and precautions
When using high doses of the medicine, monitor the urea concentration in serum and urine.
In cases of severe liver dysfunction, the infusion rate should be adjusted individually to avoid gastrointestinal disorders, such as nausea and vomiting.
Children
There are no data on the use of Hepa-Merz in children.
Hepa-Merz and other medicines
Tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
No interactions between Hepa-Merz and other medicines are known.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor before using this medicine.
Pregnancy
There are insufficient studies on the safety of using Hepa-Merz during pregnancy; therefore, avoid using the medicine during pregnancy. However, if the use of the medicine in a pregnant woman is necessary, the doctor should consider the potential benefits versus the risks before making a decision.
Breastfeeding
It is not known whether L-ornithine L-aspartate (the active substance of Hepa-Merz) passes into breast milk. Avoid using the medicine during breastfeeding. However, if the use of the medicine in a breastfeeding woman is necessary, the doctor should consider the potential benefits versus the risks before making a decision.
Driving and using machines
The ability to drive and use machines may be reduced due to the disease being treated with Hepa-Merz.
3. How to use Hepa-Merz
Dosage
Always use this medicine exactly as your doctor has told you. If you are not sure, consult your doctor or pharmacist.
Usually, up to 20 g (4 ampoules) per day is administered.
In pre-coma and coma states, up to 40 g (8 ampoules) per day, depending on the patient's condition.
If you feel that the effect of the medicine is too strong or too weak, consult your doctor or pharmacist.
Method of administration
Intravenous administration.
Before administration, dissolve the contents of the ampoule in an infusion solution. Hepa-Merz can be administered in all commonly used infusion solutions. No incompatibilities related to dissolution have been observed so far.
It is recommended to prepare the infusion solution immediately before administration.
Due to the risk of vein damage, do not administer more than 6 ampoules in 500 ml of solution.
Infusion rate: maximum 5 g (1 ampoule)/hour.
Do not administer intra-arterially.
Using more than the recommended dose of Hepa-Merz
No symptoms of overdose have been observed with Hepa-Merz so far.
In case of overdose, symptomatic treatment is used.
4. Possible side effects
Like all medicines, Hepa-Merz can cause side effects, although not everybody gets them.
Uncommon side effects (less than 1 in 100 people):nausea.
Rare side effects (less than 1 in 1,000 people):vomiting.
Frequency not known (cannot be estimated from the available data):
hypersensitivity, allergic reactions (anaphylactic).
Nausea and vomiting are usually transient and do not require discontinuation of the medicine.
They subside after reducing the dose or infusion rate.
Reporting side effects
If you experience any side effects, including any side effects not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects will help gather more information on the safety of the medicine.
5. How to store Hepa-Merz
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging.
The expiry date refers to the last day of the given month.
Store in the original packaging.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the pack and other information
What Hepa-Merz contains
The active substance is L-ornithine L-aspartate.
1 ampoule (10 ml) of the concentrate for solution for infusion contains 5 g of L-ornithine L-aspartate.
The excipient is water for injections.
What Hepa-Merz looks like and contents of the pack
Hepa-Merz, concentrate for solution for infusion, is a clear solution.
The pack contains 10 ampoules of 10 ml each.
For more detailed information, consult the marketing authorization holder or the parallel importer.
Marketing authorization holder in Romania, the country of export:
Merz Pharmaceuticals GmbH
Eckenheimer Landstrasse 100
60318 Frankfurt am Main
Germany
Manufacturer:
MERZ PHARMA GmbH & Co. KGaA
Ludwigstraße 22
64354 Reinheim
Germany
Parallel importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Repackaged by:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Romania, the country of export:7377/2006/01
Parallel import authorization number: 416/22 Date of approval of the leaflet: 22.11.2022
[Information about the trademark]
- Country of registration
- Prescription requiredNo
- Marketing authorisation holder (MAH)Merz Pharmaceuticals GmbH
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to Hepa-mezhDosage form: Granulate, 3 g/5 gActive substance: ornithine oxogluratePrescription requiredDosage form: Granulate, 3 g/5 gActive substance: ornithine oxogluratePrescription requiredDosage form: Granulate, 3 g/5 gActive substance: ornithine oxogluratePrescription required
Alternatives to Hepa-mezh in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to Hepa-mezh in Spain
Alternative to Hepa-mezh in Ukraine
Online doctors for Hepa-mezh
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Hepa-mezh – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
